SG Americas Securities LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• SG Americas Securities LLC cut its stake in Structure Therapeutics by 74.4% in Q4, selling 29,553 shares and retaining 10,147 shares valued at $706,000.
• The company reported Q4 EPS of ($0.49), missing the ($0.35) estimate, and sell‑side analysts forecast about −0.82 EPS for the current fiscal year.
• Analysts' consensus is a "Moderate Buy" with a $110 average price target, while GPCR trades near $54.51 and has a one‑year range of $15.00–$94.90.

SG Americas Securities LLC lowered its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 74.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,147 shares of the company's stock after selling 29,553 shares during the period. SG Americas Securities LLC's holdings in Structure Therapeutics were worth $706,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of GPCR. State of Wyoming purchased a new position in Structure Therapeutics in the second quarter worth $28,000. EverSource Wealth Advisors LLC boosted its position in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company's stock worth $30,000 after purchasing an additional 901 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 39.1% in the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company's stock worth $114,000 after purchasing an additional 1,146 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Structure Therapeutics in the second quarter worth $129,000. Finally, PNC Financial Services Group Inc. boosted its position in Structure Therapeutics by 9.4% in the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company's stock worth $135,000 after purchasing an additional 413 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on GPCR. Leerink Partners reissued an "outperform" rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Citizens Jmp cut their price objective on Structure Therapeutics from $120.00 to $113.00 and set a "market outperform" rating on the stock in a research report on Friday, February 27th. JPMorgan Chase & Co. boosted their price objective on Structure Therapeutics from $65.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, January 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright cut their price objective on Structure Therapeutics from $114.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $110.00.

Structure Therapeutics Price Performance

Shares of GPCR opened at $54.51 on Friday. The firm has a market cap of $3.86 billion, a PE ratio of -69.00 and a beta of -1.17. The stock's fifty day moving average price is $61.18 and its two-hundred day moving average price is $53.68. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.00 and a 1 year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.